CP50: Bayer Corp.
The company, which created aspirin in 1897, makes health-care products (prescription pharmaceuticals, OTC drugs, and animal health care), specialty materials (plastics and high-performance materials), and agricultural products (for crop protection and home garden care). It operates in the U.S. through Bayer Corp.
Overall Bayer, also referred to as Bayer Group, has some 350 operating companies worldwide. Bayer AG defines common values, goals and strategies for the entire Group. The three subgroups and three service companies operate independently, led by the management holding company. The Corporate Center supports the Group Management Board in its task of strategic leadership.
Dr. Marijn Dekkers
Chairman of the Board of Management
Dr. Marijn Dekkers became Chairman of the Board of Management of Bayer AG on October 1, 2010. He succeeded Werner Wenning, who retired as of that date. <br><br> Dekkers joined Bayer AG as a member of the Board of Management on January 1, 2010, also serving as interim head of the Bayer HealthCare subgroup from May 1 until August 14, 2010. Before coming to Bayer, Dekkers was President and CEO of the U.S. laboratory equipment manufacturer Thermo Fisher Scientific Inc., Waltham, Mass.
Member of the board of management, CFO
Baumann is the member of the Bayer AG Board of Management responsible for Finance (Chief Financial Officer) and for the Europe region. <br><br> After studying economics at RWTH Aachen University and the University of Cologne, he joined Bayer AG in 1988. His first duties were in the Corporate Finance Department in Leverkusen. In 1991 he transferred to Bayer Hispania Comercial in Barcelona, Spain, to take up a position as controller, becoming assistant to the managing director in 1995.
Member of the board of management
Malik was appointed to the Bayer AG board of management effective Feb.1, 2014. He is responsible for Innovation and the North America and Latin America regions. Malik joined Bayer in 1995 as head of metabolism and oncology Europe in the former Pharmaceuticals Business Group. He subsequently served as head of global medical development before being appointed head of global development.